{
    "answer": "According to the 'Novartis Q4 2024 Condensed Financial Report \u2013 Supplementary Data', for Cosentyx's immunology segment:\n*   **Full year 2024 (reported basis):** USD 6.1 billion (+23%).\n*   **Full year 2024 (constant currency basis):** USD 6.1 billion (+23%).\n*   The reported change compared to full year 2023 is \"no change\", since the full year 2023 data was USD 1.575 billion, and the full year 2024 reported sales were USD 6.1 billion.\n*   The constant currency change compared to full year 2023 is \"no change\", since the full year 2023 constant currency sales were USD 1.575 billion, and the full year 2024 constant currency sales were USD 6.1 billion.",
    "ground_truth": "$6,141,000,000; 23% increase (reported); 25% increase (constant currency)",
    "rewards": [
        0,
        0,
        0,
        0,
        0,
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 7,
    "search count": 5,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        866,
        2346,
        3963,
        5376,
        7450,
        7904,
        9778
    ]
}